# Tesofensine

> Tesofensine is an investigational oral compound that inhibits reuptake of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine. Originally studied for neurodegenerative conditions, it was found in early trials to reduce appetite and body weight, and has since been studied specifically for obesity. Reported average weight reductions in early trials were notable relative to some older appetite suppressants, though development has been slower than for injectable incretin therapies. It has not received widespread regulatory approval, and large-scale modern trial data remain limited compared with GLP-1-class agents.

- URL: https://www.lifeconverted.com/peptides/tesofensine
- Also known as: NS2330
- Primary category: Weight Management
- Effectiveness rank: #20 in Weight Management
- Evidence level: Moderate evidence
- Route: Oral
- Dose range: 0.25-1 mg
- Dose tiers: low 0.25 mg; moderate 0.5 mg; high 1 mg
- Half-life: Approximately 8 days, unusually long for an oral central-nervous-system agent
- Timing: Morning
- Cycle: Studied in trials over periods of roughly 6 months to 1 year on, Not well established; extended use raises cardiovascular monitoring considerations off (Its long half-life means effects and side effects may persist well after the last dose.)
- Storage: Store tablets at room temperature, protected from moisture and light, per manufacturer/trial labeling.

## Mechanism of action

Tesofensine blocks presynaptic reuptake of serotonin, norepinephrine, and dopamine, increasing their availability in synapses within brain regions that regulate appetite and reward. This is thought to reduce food intake by altering hunger and satiety signaling as well as food-related reward response, distinguishing its mechanism from incretin-based agents.

## Reported benefits

- Associated with appetite reduction and body-weight loss in early clinical trials
- Oral administration
- Distinct central-nervous-system mechanism from GLP-1-class agents
- Once-daily dosing schedule studied in trials

## Reported side effects

- Increased heart rate and blood pressure reported in trials
- Dry mouth, nausea, constipation, and insomnia
- Potential mood or psychiatric effects given its central nervous system activity
- Long-term cardiovascular and psychiatric safety data remain limited

## Common protocols

- Trial-based daily oral dosing with cardiovascular monitoring

## Stacking notes

Combining with other stimulant-like or monoamine-active compounds is not supported by evidence and may increase cardiovascular risk.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer